NASDAQ · STOK
Stoke Therapeutics, Inc.
Healthcare · Biotechnology
$26.76▲ 1.78% ($0.47)today
As of 3:01 PM ET
Market cap
$1.73B
P/E
N/M
EPS (TTM)
-$3.56
Next earnings
Valuation
Revenue & margin DCF
Verdict: expensive. Price above Base.
The price needs 62.8% revenue growth a year for 10 years. Our scenarios assume 14.1–24.4%.
That's below its past 3-year pace of 145.9%.
Value per share
Base case
$5.41
Price used $26.76 is 5.0× this
USD · TTM ending Sep 30, 2026 · Price Nov 2, 8:01 PM UTC
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
Revenue each value needs
Revenue today $28.2M. The price needs $3.7B by 2036. Base case: $169M. At its recent pace: $228B. Bear to Bull: $105M to $251M.
Revenue today $28.2M. The price needs $3.7B by 2036. Base case: $169M. At its recent pace: $228B. Bear to Bull: $105M to $251M.
Revenue in 2036
today $28.2M
+$3.5Bmore than the Base case · 21.7×
Value per share · Base case
$5.41
Price $26.76
5.0× this
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 10.2%
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
USD · TTM ending Sep 30, 2026 · Price Nov 2, 8:01 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 2.34% over the last year. Revenue declined 86.28% over the trailing twelve months. Operating margin moved from 13.23% to -913.12%.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -913.12%. A decisive move in revenue — currently down 86.28% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
13
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Mar 15, 2027
Q4 FY26 · EPS est -$1.06 · Revenue est $8.1M
Same quarter, year over year
FY26 YTD -429.4%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q3 combined -$2.80 vs $0.85 · 0 of 3 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
FY25
FY24
FY23
—
—
—
—
Fiscal year totals
- FY25
- -$0.12
- n/m
- FY24
- -$1.68
- —
n/m: last year’s figure was zero, a loss or too small to compare against
Q3 FY26
Reported Oct 29, 2026 · Latest
HoverTap a cell to inspect
Actual
-$1.08
Estimate
-$0.93
Year over year
n/m
Vs prior quarter
n/m
Institutional Sentiment
Stoke Therapeutics, Inc. · STOK
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.